Mineralys Therapeutics, Inc./$MLYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Ticker
$MLYS
Sector
Primary listing
Employees
51
Headquarters
Website
MLYS Metrics
BasicAdvanced
$2.9B
-
-$3.49
-0.30
-
Price and volume
Market cap
$2.9B
Beta
-0.3
52-week high
$39.20
52-week low
$8.69
Average daily volume
2M
Financial strength
Current ratio
15.121
Quick ratio
14.654
Profitability
EBITDA (TTM)
-203.009
Management effectiveness
Return on assets (TTM)
-38.80%
Return on equity (TTM)
-63.21%
Valuation
Price to book
7.78
Price to tangible book (TTM)
7.78
Price to free cash flow (TTM)
-10.515
Free cash flow yield (TTM)
-9.51%
Free cash flow per share (TTM)
-3.528
Growth
Earnings per share change (TTM)
27.33%
Bulls say / Bears say
Mineralys’ lorundrostat showed a 9.1 mmHg placebo-adjusted reduction in systolic blood pressure at a 50 mg dose after six weeks, matching the efficacy of industry leaders (Reuters)
Mineralys aims to submit lorundrostat data to the FDA by the end of 2025, paving the way for a possible regulatory filing and market launch in 2026 (Reuters)
With hypertension affecting over 1 billion people globally, Mineralys’ aldosterone synthase inhibitor targets a vast addressable market, offering substantial growth potential (Reuters)
Lorundrostat has shown cases of hyperkalaemia in clinical trials, with a 1.1% incidence similar to AstraZeneca’s baxdrostat, raising patient safety concerns (Reuters)
AstraZeneca’s baxdrostat is projected to reach peak annual sales of over $5 billion, creating substantial competitive pressure and potentially limiting the market share for Mineralys’ lorundrostat (Reuters)
Lorundrostat achieved a 9.1 mmHg placebo-adjusted drop in systolic blood pressure, which falls short of the 10–12 mmHg decrease physicians typically expect, possibly limiting clinical adoption (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mineralys Therapeutics, Inc. stock?
Mineralys Therapeutics, Inc. (MLYS) has a market cap of $2.9B as of September 15, 2025.
What is the P/E ratio for Mineralys Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) stock is 0 as of September 15, 2025.
Does Mineralys Therapeutics, Inc. stock pay dividends?
No, Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Mineralys Therapeutics, Inc. dividend payment date?
Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. (MLYS) has a beta rating of -0.3. This means that it has an inverse relation to market volatility.